Asia Pacific Sexually Transmitted Diseases Testing Market By Disease Type, By the Location of Testing Testing, By Country, Opportunity Analysis and Industry Forecast, 2021-2027

The Asia Pacific Sexually Transmitted Diseases (STD) Testing Market is expected to witness market growth of 4.5% CAGR during the forecast period (2021-2027).

Some STDs like chlamydial and gonococcal infections in women need etiological identification of STDs that are expensive and advanced laboratory procedures. However, such laboratory tests are not accessible in the developed and developing nations for the patient's assessment, and those that are available are not helpful in determining rapid treatment recommendations. The lack of simple & quick diagnostics for the detection of most STDs, the high cost of existing STD laboratory testing, and the lack of requisite laboratory infrastructure are creating lucrative opportunities for the key market players.

In India, the government has recognized Sexually transmitted diseases (RTIs/STIs) and other reproductive tract infections (RTIs/STIs) as a public health issue, particularly because of their link to HIV infection. RTI/STI prevention, control, and management is a well-known technique for reducing reproductive morbidity among the sexually active population while also regulating the spread of HIV/AIDS in the country. In addition, National AIDS Control Programme run by the Government of India has created more awareness among population along with increasing STD testing in rural areas. Additionally, the introduction of various advanced and effective testing methods in this region is expected to fuel the regional market growth.

The China market dominated the Asia Pacific Sexually Transmitted Diseases (STD) Testing Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $13.00 billion by 2027. The Japan market is poised to grow a CAGR of 3.9% during (2021 - 2027). Additionally, The India market is expected to experience a CAGR of 5.1% during (2021 - 2027).

Based on Disease Type, the market is segmented into Chlamydia, Herpes simplex, Gonorrhea, Syphilis, Human papillomavirus (HPV), and Other Disease. Based on the Location of Testing, the market is segmented into Laboratory Testing and Point of care (POC) Testing. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., DiaSorin Molecular LLC, Danaher Corporation, Bio-Rad Laboratories, Inc., and OraSure Technologies, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Disease Type

• Chlamydia
• Herpes simplex
• Gonorrhea
• Syphilis 
• Human papillomavirus (HPV)
• Other Disease

By Location of Testing

• Laboratory Testing
• Point of care (POC) Testing

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• BioMérieux S.A.
• Abbott Laboratories
• Becton, Dickinson and Company
• Hologic, Inc.
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• DiaSorin Molecular LLC
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• OraSure Technologies, Inc.

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free